Carcinoma

Japanese drugmaker Eisai’s US subsidiary has obtained breakthrough therapy status from the US Food and Drug Administration (FDA) for its anticancer agent Lenvima (lenvatinib mesylate) to treat advanced or metastatic renal cell carcinoma.

Lenvatinib is an orally administered multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode, which selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2 and VEGFR3) and fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

It also inhibits other proangiogenic and oncogenic pathway-related RTKs, including the platelet-derived growth factor (PDGF) receptor PDGFRa, KITm and RET, involved in tumour proliferation.

The designation was provided based on the results of a Phase II clinical trial (Study 205) of lenvatinib in advanced or metastatic renal cell carcinoma following one prior vascular endothelial growth factor-targeted therapy.

"Both the lenvatinib plus everolimus group and the lenvatinib alone group demonstrated an improvement in objective response rate compared with the everolimus alone group."

According to the firm, the trial results of the combination of lenvatinib plus everolimus showed a significant extension in progression-free survival (PFS), the study’s primary endpoint, compared with everolimus alone.

See Also:

In addition, the study showed an extension in PFS compared with everolimus alone. Both the lenvatinib plus everolimus group and the lenvatinib alone group demonstrated an improvement in objective response rate compared with the everolimus alone group.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lenvatinib received orphan drug status in the US, Japan and Europe to treat refractory thyroid cancer. It is also undergoing regulatory review in nine countries.

The company is carrying out global Phase III study of lenvatinib in hepatocellular carcinoma, as well as Phase II studies in several other tumour types such as endometrial carcinoma and non-small cell lung cancer.

Image: Metastatic renal cell carcinoma. Photo: courtesy of Yale Rosen.